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Protection against oxidative damage caused by
excessive reactive oxygen species (ROS) by an anti-
oxidant network is essential for the health of tissues,
especially in the cardiovascular system. Here, we
identified a gene with important antioxidant features
by analyzing a null allele of zebrafish ubiad1, called
barolo (bar). bar mutants show specific cardiovas-
cular failure due to oxidative stress and ROS-medi-
ated cellular damage. Human UBIAD1 is a nonmito-
chondrial prenyltransferase that synthesizes CoQ10
in the Golgi membrane compartment. Loss of
UBIAD1 reduces the cytosolic pool of the antioxidant
CoQ10 and leads to ROS-mediated lipid peroxi-
dation in vascular cells. Surprisingly, inhibition of
eNOS prevents Ubiad1-dependent cardiovascular
oxidative damage, suggesting a crucial role for
this enzyme and nonmitochondrial CoQ10 in NO
signaling. These findings identify UBIAD1 as a nonmi-
tochondrial CoQ10-forming enzyme with specific
cardiovascular protective function via the modula-
tion of eNOS activity.
INTRODUCTION
Reactive oxygen species (ROS) play an important role in signal
transduction and physiological regulation of the cardiovascular
system by facilitating various biological responses, including
senescence in heart and endothelial cells (ECs) (Lander et al.,
1996; Finkel, 2003; Finkel and Holbrook, 2000; Hare and Stam-
ler, 2005; D’Autre´aux and Toledano, 2007). In cardiovascular
tissues, ROS are normally produced in response to RTK and
GPC receptor signaling, as well as during mechanical (shear)
stress. ROS help regulate cardiovascular homeostasis (Colavitti
et al., 2002; Werner, 2004; Ushio-Fukai, 2006). An antioxidant504 Cell 152, 504–518, January 31, 2013 ª2013 Elsevier Inc.network is required to balance these ROS and prevent oxidative
damage, which may contribute to cardiovascular pathologies
(Finkel, 2003; Giordano, 2005; Kuster et al., 2010). Although
several enzymes responsible for ROS production in ECs have
been identified, many of the molecules involved in the endoge-
nous antioxidant network are unknown.
A molecule known to play an important antioxidant role in the
cardiovascular system is CoQ10 (also known as Coenzyme Q10
or ubiquinone) (Pepe et al., 2007; Kumar et al., 2009). CoQ10
is the only endogenously synthesized lipid-soluble antioxidant
(Crane, 2007; Bentinger et al., 2007). It is available in the mem-
branes of the Golgi, where it is present at an even higher concen-
tration than in themitochondria, as well as in plasmamembranes
(Kalen et al., 1987; Crane, 2001; Bentinger et al., 2008). Although
the biosynthesis of CoQ10 in mitochondria has been studied
in detail, only a limited amount of data is available in regards
to the synthesis of cellular membrane CoQ10. Several in vivo
experiments suggest that CoQ10 synthesis may also occur in
the Golgi and endoplasmic reticulum membranes, providing
the cellular membrane CoQ10 pool (Kale´n et al., 1990). However,
although hypothesized, a ‘‘nonmitochondrial’’ CoQ10 biosyn-
thetic enzyme has not been identified (Bentinger et al., 2010).
Identification of such an enzyme could be extremely useful in
order to devise strategies to counteract the excess of ROS
responsible for cellular oxidative damage (such as lipid peroxi-
dation, protein nitrosylation, and DNA oxidation) and therefore
balance redox signaling especially in cardiovascular tissues.
CoQ10 is a mobile lipophilic electron carrier that is critical
for electron transfer both in the mitochondrial membrane for
respiratory chain activity as well as in Golgi and plasma mem-
branes for NAD(P)H-oxidoreductase-dependent reactions such
as in NO synthesis (Navas et al., 2007). Endothelial nitric oxide
synthase (eNOS) is a critical regulator of cardiovascular func-
tions by generating nitric oxide (NO), which is an important medi-
ator of cardiovascular homeostasis (Alp and Channon, 2004;
Fo¨rstermann and Sessa, 2012). As in the case with nonmito-
chondrial CoQ10, eNOS is specifically localized in the Golgi
and plasma membrane of heart and endothelial cells, and it
can be differentially regulated in these two cellular compart-
ments (Fulton et al., 2002). Different reports have suggested
that CoQ10 may improve endothelial dysfunction by ‘‘recou-
pling’’ eNOS and modulating NO-related signaling (Chew and
Watts, 2004; Tsai et al., 2012).
Here, we identify UBIAD1 as an enzyme for CoQ10 synthesis
at the level of Golgi membranes and show that it is critical for
oxidative stress protection. In particular, UBIAD1 protects car-
diovascular tissues from eNOS-dependent oxidative stress. We
propose a functional link between UBIAD1, CoQ10, and NO
signaling during cardiovascular development and homeostasis.
RESULTS
Oxidative Stress and Cardiovascular Failure
Characterize barolo Mutants
By forward genetic screens for cardiovascular mutants (2005
Tuebingen screen; Jin et al., 2007), we identified mutations in
the barolo (bar) gene (bart31131 and bars847). These mutations
are recessive and show complete penetrance and expressivity.
bar mutants show distinct cranial vascular hemorrhages and
pericardial edema in the context of wild-type body morphology
(Figure 1A). To examine whether this phenotype is associated
with cardiovascular defects, we crossed the mutations into
Tg(kdrl:GFP)s843 (Figure 1B). The hemorrhagic phenotype in bar
mutants is accompanied by endothelial regression and fragmen-
tation in the cranial and trunk vascular compartments (Figures
1C and 1D). Time-lapse analyses of trunk vasculature indicate
that the bar phenotype starts around 36 hr postfertilization
(hpf) (Movies S1, S2, S3, and S4) and that it is not due to general
loss of blood flow. The cardiac edema of bar mutants is caused
by a gradual breakdown of endocardial and myocardial cells in
the heart, leading to the collapse of the heart between 60 and
72 hpf (data not shown). All these features lead to the complete
cardiac and vascular organ failure by 72 hpf in bar mutant
embryos.
Cardiovascular failure is related to altered redox signaling and
an increased production of ROS (Hare and Stamler, 2005). bar
mutants compared to wild-type siblings show altered redox
balance and oxidative stress features evaluated as an increase
of the NADP/NADPH ratio and as an overexpression of antioxi-
dant genes, respectively (Figures 1E and 1F). Increase of ROS
production occurs specifically in cardiovascular tissues as
demonstrated by measuring oxidizing species in ECs of bar
mutants using the selective and stable ROS detector CellROX
(Figure 1G). We also measured S-nitrosylation levels on heart
and blood vessel sections of bar mutants. bar mutants show
higher levels of S-nitrosylated proteins in heart and blood vessel
cells as well as in pronephros as measured by an antibody
against S-nitroso-cysteine (SNO-Cys) (Figure 1H). A high level
of S-nitrosylated proteins is normally associated with altered
redox signaling and cellular protection against oxidative stress
(Stamler et al., 2001; Hess et al., 2005; Sun and Murphy, 2010).
We found that cardiovascular tissues from bar mutants
are positive for 8-hydroxy-20-deoxyguanosine (8-OHdG), a free
radical-induced oxidative lesion in DNA (Figure 1I). Analyses of
heart and blood vessel sections show that both myocardial
and endothelial tissues of bar mutants exhibit ROS-mediatedDNA damage compared to controls. Indeed, endothelial and
endocardial cells in bar mutants were positive for TUNEL stain-
ing and show typical morphological features of apoptotic cells at
this stage (Figure 1L). In summary, both mutant embryos
carrying the barolo mutation show increased oxidative stress,
DNA damage, and cell death specifically in blood vessels and
the heart.
We determined that bar encodes Ubiad1 (UbiA-domain
containing protein 1) (Figure 1M). Sequence analyses show
that the bart31131 mutant allele contains a nonsense mutation
(123 T > A) in ubiad1 introducing a premature stop codon at
amino acid position 41, likely generating a null allele. The second
allele of bar (bars847) bears a base change (185 T > A) leading to
the substitution of a conserved leucine residue to glutamine at
amino acid position 62 (Ubiad1L62Q) (Figure 1N). bars847 shows
the same phenotypical features as bart31131 except the pheno-
type is delayed by 12 hr (Figures S1A–S1E and S1T available on-
line). Both bar allele mutants do not express Ubiad1 (Figure 1O)
and are fully rescued by Ubiad1 mRNA expression. Ubiad1L62Q
mRNA does not rescue the bart31131 mutant indicating that this
amino acid mutation is sufficient to knock out Ubiad1 activity
(Figure 1P). To confirm that Ubiad1 regulates cardiovascular
protection and survival, we knocked down Ubiad1 expression
using an antisense morpholino oligonucleotide. Ubiad1 mor-
phants show the same hemorrhagic phenotype and cardiovas-
cular defects as bar mutants (Figures S1F–S1I).
Analyses of ubiad1 mRNA expression in developing zebrafish
embryos reveal a ubiquitous expression at 24 hpf in addition
to a distinct expression in the heart at 48 hpf (Figures S1J–
S1L), in agreement with mammalian expression data (Nakagawa
et al., 2010). In addition, cell transplantation and tissue-specific
rescue experiments showed that Ubiad1 functions autono-
mously within endothelial and endocardial cells (Figures S1M–
S1P and Table S1).
These data indicate that loss of ubiad1 triggers a progressive
cardiovascular failure by increasing oxidative stress and apo-
ptosis in heart and blood vessels suggesting a role for Ubiad1
as a controller of redox state andROS levels in vertebrate cardio-
vascular tissues (Figure S1Q). Thereby, bar represents a unique
model to study oxidative stress conditions and redox signaling
during zebrafish development.
UBIAD1 Is a CoQ10 Biosynthetic Enzyme
Ubiad1 is conserved among species and contains an UbiA pre-
nyltransferase domain, present also in the vertebrate protein
Coq2. So far, the mitochondrial enzyme Coq2 is the only verte-
brate enzyme known to synthesize CoQ10 through the prenyla-
tion of 4-hydroxybenzoic acid by oligoprenyl diphosphates
(Forsgren et al., 2004). The CoQ10 molecule is composed of
a redox active benzoquinone ring, which is connected to a poly-
isoprenoid side chain of variable length (typically 9/10 units in
vertebrates) (Crane, 2001). As with Coq2, we speculate that
Ubiad1might catalyze the biosynthesis of CoQ10. Wemeasured
CoQ10 levels in bar mutants and ubiad1 morphants by HPLC-
MS (Figures 2A and 2B). The absence of Ubiad1 in zebrafish
larvae significantly reduces CoQ10 levels (Figure 2C), whereas
cholesterol levels are not significantly affected (Figure S2A). By
the time course of synthesis analyses, we found that CoQ10Cell 152, 504–518, January 31, 2013 ª2013 Elsevier Inc. 505
Figure 1. Loss of Ubiad1 Induces Cardiovascular Failure in Zebrafish Embryos by Increasing Oxidative Stress
(A and B) Siblings (sib) and barolot31131 (bar) mutant embryos at 65 hpf. (A) Vascular hemorrhages (asterisks) and heart failure (arrowhead) in bar.
(B) Tg(kdrl:GFP)s843 bar show vascular integrity defects (arrows) and collapsed endocardium (arrowhead). Scale bar, 300 mm.
(legend continued on next page)
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increases during zebrafish embryonic development and is
almost entirely produced by the zygote without any contribution
from the yolk sac (Figure S2B). On the other hand, a significant
amount of embryonic cholesterol is provided by the yolk sac
throughout early development (Figure S2C). These data suggest
that de novo zygotic synthesis of CoQ10 by Ubiad1 (and/or
Coq2) is required for zebrafish development.
To test whether it is the absence of CoQ10 synthesis in zebra-
fish embryos that causes the bar phenotype, we injected CoQ10
in single-cell stage bar mutants (Figure 2D). Three different
CoQ10 formulations rescue bar mutants, suggesting that the
intake of CoQ10 in Ubiad1 deficient embryos may restore nor-
mal cardiovascular development. A recent paper reports that
UBIAD1 is required for Vitamin K2 production (Nakagawa
et al., 2010); however, our data indicate that a lack of Vitamin
K2 is not responsible for the cardiovascular phenotype in bar
mutants (Figures 2D and S2D–S2K).
To provide biochemical evidence that Ubiad1 is able to
synthesize CoQ10, we performed metabolic studies in zebrafish
embryos by analyzing the ability of bar mutants to convert
hydroxy-4-benzoic acid to CoQ10 (Figure 2E). We confirmed
that administration of 13C6-labeled hydroxy-4-benzoic acid
(hydroxy-4-benzoic acid-13C6) is metabolized to CoQ10-
13C6
in zebrafish embryos by injecting this C13-labeled precursor in
zebrafish embryos at one-cell stage. After 72 hpf of incubation,
lipids were extracted and analyzed by HPLC-MS to quantify the
amount of CoQ10-13C6 formed (Figure 2E). bar mutants show
a reduced CoQ10-13C6 production compared to wild-type
siblings. CoQ9-13C6 production was also impaired (Figure 2F),
indicating that zebrafish larvae can synthesize both CoQ9 and
CoQ10 as can human cells (Turunen et al., 2004). Therefore,
Ubiad1 is a 4-OH-benzoic acid-prenyl-tranferase enzyme
required for CoQ10 and CoQ9 biosynthesis in vivo.
Ubiad1 and HMG-CoA Reductase inhibitors act in the Meval-
onate Pathway for CoQ10-Dependent Cardiovascular Oxidative
Stress Protection.(C) Tg(Fli1a:GFP)y1 bar show severe loss of cranial network vasculature and frag
(D) Confocal images of trunk vasculature of Tg(kdrl:GFP)s843 bar report loss of E
(E) NADP+/NADPH ratio at 60 hpf. Increased ratio is indicative of oxidative stres
(F) Real-time PCR analysis show upregulation of the antioxidant genes glutathione
means ± SD.
(G) Quantification of oxidative stress level in ECs derived from Tg(kdrl:GFP)s843 e
(H) Immunofluorescence analyses for S-nitroso-cysteine (SNO-Cys, red) and DN
transverse sections; upper right: quantification of SNO-Cys positive cells. Lower le
positive cells. Scale bar, 75 mm. Specific SNO-Cys signals were also detectable
(I) Immunofluorescence analyses for 8-hydroxy-20deoxyguanosine (8OHdG, red
transverse sections; upper right: quantification of 8OHdG positive cells. Scale
quantification of 8OHdG positive. Scale bar, 20 mm. bar show specific 8OHdG stai
(L) TUNEL-positive (red) cells show apoptosis in endocardium and endothelium (ar
upper right: quantification of TUNEL-positive cells. Lower left: transverse sections
Scale bars, 20 mm.
(M) Genetic map of the zebrafish barolo locus. The SSLPmarkers (z22307) was us
(N) Schematic representation of zebrafish Ubiad1. UbiA:UbiA domain.
(O) Western blot analysis of protein extracts from bars847 and bart31131 and respe
(P) Embryos from bars847 and bart31131 heterozygote intercrosses were injected
protein cherry (ctrl). bars847 as well as bart31131 were not rescued by microinjecti
A, atrium; V, ventricle; DA, dorsal aorta; PCV, posterior cardinal vein; BuA bulbus
means ± SEM. **p < 0.01, ***p < 0.001.
See also Figure S1, Table S1, and Movies S1, S2, S3, and S4.The rate-limiting reaction in the biosynthesis of CoQ10 is
the transfer of the polyprenyl-pyrophosphate (polyprenyl-PP)
chain, derived from mevalonate, on to 4-OH-benzoic acid,
derived from tyrosine metabolism (Bentinger et al., 2008) (Fig-
ure 2A). We reduced the pool of polyprenyl-PP available for
CoQ10 synthesis by treating zebrafish embryos with statins,
inhibitors of its precursor (e.g., mevalonate) (Figure S3A). By
blocking HMG-CoA reductase, statins impair the mevalonate
and FPP synthesis, which is mandatory to synthetize the poly-
prenyl-PP chain (Figure 2A). Wild-type embryos (ubiad1+/+)
treated with statin developed a bar-like phenotype (Figures
3A–3C). Statin treatments efficiently reduced CoQ10 synthesis
without interfering with cholesterol levels, probably because
statin treatment blocks de novo cholesterol biosynthesis but
does not interfere with the maternally provided cholesterol
(Figures 3D and 3E). Zebrafish embryos treated with the squa-
lene synthase inhibitor (SQI) or with farnesyl or geranyl-geranyl
tranferase inhibitors (FTI or GGTI) did not exhibit a bar-like
phenotype (Figure S3B), indicating that the absence of
CoQ10 is the cause of the statin-induced cardiovascular
oxidative phenotype. Furthermore, while treatment with a
low-dose of statin did not produce any phenotype in wild-
type (ubiad1+/+) embryos, it caused a bar-like phenotype in
embryos heterozygous for ubiad1 (ubiad1+/) (Figures 3F–3I).
The statin-dependent phenotype in embryos was efficiently
rescued by exogenous administration of liposomal CoQ10
(Figures 3J and 3K and S3C). To address the role of the meval-
onate pathway in protection from oxidative stress in vivo, we
measured ROS levels in zebrafish embryos treated with
HMG-CoA reductase inhibitors. A ROS level increase is de-
tected in statin-treated zebrafish embryos, and this oxidative
stress was fully rescued by CoQ10 treatment (Figure 3L). These
data suggest that HMG-CoA reductase and Ubiad1 are on the
same metabolic pathway to produce CoQ10 as a potent anti-
oxidant molecule which protects cardiovascular tissues during
development.mented endothelium (arrow) at 65 hpf.
Cs at the level of Se, DA (arrows), and PCV. Scale bar, 50 mm.
s state.
peroxidase1a (gpx1a) and heme-oxigenase1 (hmox1) in bar at 56 hpf. Data are
mbryos at 56 hpf.
A (blue) in Tg(kdrl:GFP)s843 bar and sib embryos at 60 hpf. Upper left: heart
ft: trunk vasculature transverse sections; lower right: quantification of SNO-Cys
in pronephros and myocardium of bar (arrowhead).
) and DNA (blue) in Tg(kdrl:GFP)s843bar and sib at 56 hpf. Upper left: heart
bars, 50 mm. Lower left: trunk vasculature transverse sections; lower right;
ning in endocardial and endothelial cells (arrows) andmyocardium (arrowhead).
rows). Upper left: heart transverse sections of Tg(kdrl:GFP)s843 bar s847 and sib ;
of trunk vasculature; lower right: quantification of positive cells in DA and PCV.
ed to identify the ‘‘zero recombinant’’ region by analysis of 987 diploid mutants.
ctive siblings at 72 hpf.
with mRNA encoding for wild-type ubiad1 mRNA, ubiad1L62Q or fluorescent
on of ubiad1L62Q mRNA.
arteriosus; PD, pronephric ducts; E, endocardium; M myocardium. All data are
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Figure 2. Ubiad1 Is a Prenyltranferase Required for CoQ10 Biosynthesis in Vertebrates
(A) Schematic representation of the 13C-based metabolomic approach used to demonstrate that Ubiad1 is a 4-OH-benzoic acid-prenyltranferase enzyme.
Coenzyme Q10 (CoQ10) biosynthesis starts with formation of a hydroxy-benzoic acid head group (4-OH-benzoic acid) and a lipophilic polyisoprenoid tail
(polyprenyl-PP). The aromatic precursor of the benzoquinone ring (4-OH-benzoic acid) derives from tyrosine. Synthesis of the polyisoprenoid tail takes place in
the cytoplasm starting from acetyl-CoA through the mevalonate pathway (which is shared with the cholesterol and dolichol biosynthetic pathways). The poly-
isoprenoid tail is assembled by polyprenyl diphosphate synthase, which is responsible for determining the number of isoprene units (designated as n). Next is the
condensation of the polyisoprenoid chain with the benzoquinone ring to form the 4-hydroxy-3-polyprenyl benzoic acid intermediate (PPHB) by a 4-OH-benzoic-
polyprenyl-tranferase (UbiA-containing enzyme). The subsequent reactions (O-methylations and C-methylations, hydroxylations and decarboxylations) modify
the structure of the aromatic ring, but some of the enzymes involved are still unknown. Exogenous 4-OH-benzoic acid-13C6 containing heavy carbon element (
13C)
is administered to embryos and cells so that de novo synthesis of PPHB and therefore CoQ10 can be monitored by HPLC-MS analyses. Loss of UbiA-containing
enzymes (red) blocks the condensation of the polyisoprenoid chain with the benzoquinone ring and then formation of CoQ-13C6.
13C6-labeled compounds used or
detected in this work are shown in green.
(B) High-resolutionMS spectrum of lipid extracts fromwild-type zebrafish embryos. TheMS spectrum of the HPLC fraction containing CoQ10 reveals the analyte
as [CoQ10-Na+] at m/z = 885.6751.
(C) HPLC-MS analyses show that bar mutants are characterized by a reduced level of endogenous CoQ10 in comparison to their siblings.
(D) Exogenous supplement of CoQ10, but not of VitaminK2, can efficiently rescue bar mutants. CoQ10F1; liposomal CoQ10 preparation 0.6 mM; CoQ10F2,
LiQsorb Liposomal CoQ10 Gel 0.6 mM; COQ10 F3, SANOMIT nanoparticles CoQ10 liquid, 6.9 mM; VitK ; Liposomal Vitamin K2 0.3 mM.
(E and F) Levels of 13C6-labeled CoQ10 (CoQ10-
13C6) and
13C6-labeled CoQ9 (CoQ9-
13C6) are detected by HPLC-MS in bar mutants and siblings at 72 hpf.
Loss of Ubiad1 expression protein significantly reduces de novo CoQ10-13C6 synthesis by 78% (E) and de novo CoQ9-
13C6 synthesis by 66.5% (F). All data are
means ± SEM. **p < 0.01, ***p < 0.001.
See also Figure S2.UBIAD1 Synthesizes CoQ10 in the Golgi Compartment
To determine whether Ubiad1 could be an enzyme respon-
sible for cellular CoQ10 production, we examined its subcellular508 Cell 152, 504–518, January 31, 2013 ª2013 Elsevier Inc.localization. Ubiad1 is conserved among species and is pre-
dicted to be a transmembrane protein (Nickerson et al., 2010).
Using human primary ECs, we found that UBIAD1 localizes
in an asymmetric perinuclear region that resembles the
Golgi compartment (Figure S4A). Colocalization studies using
the Golgi-specific marker TGN46 demonstrate that endoge-
nous UBIAD1 is in the proximity of the Golgi (Figure 4A).
Also, green fluorescent protein (GFP)-tagged zebrafish Ubiad1
expressed in human ECs localizes in the same perinu-
clear region compartment and colocalizes with the Golgi
markers, GM-130 and g-adaptin (Figures 4B and4C). Further,
we observe a rapid redistribution of Ubiad1-GFP proteins in
cells treated with brefeldin A, supporting its Golgi localization
(Figure 4D).
We hypothesized that since UBIAD1 is localized in the
Golgi compartment, this enzyme might be a nonmitochondrial
CoQ10 prenyltransferase. To test this, we performed subcellular
fractionation experiments on human ECs and detected UBIAD1
only in Golgi compartments and not in mitochondria (Figure 4E).
We analyzed de novo CoQ10 synthesis in these subcellular frac-
tions by incubating ECs with the hydroxy-4-benzoic acid-13C6
precursor and observed a decrease in CoQ10-13C6 production
in Golgi compartments compared to mitochondrial fractions
when UBIAD1 expression is reduced (Figure 4F). These data
indicate that UBIAD1 is a CoQ10 biosynthetic enzyme located
in the Golgi membrane compartment where large amounts of
cellular CoQ10 are normally synthesized (Kale´n et al., 1990;
Swiezewska et al., 1993).
SCCD Mutations Protect Cardiovascular Tissues from
Oxidative Stress by CoQ10 Production
Mutations in the UBIAD1 gene are linked to the Schnyder Crys-
talline Corneal Syndrome (SCCD; OMIM 121800) (Weiss et al.,
2007; Orr et al., 2007; Yellore et al., 2007). Two commonUBIAD1
mutations found in SCCD patients lead to N102S and D112G
substitutions. We generated human UBIAD1 constructs carrying
these mutations (UBIAD1-N102S and UBIAD1-D112G) and
found that they were able to rescue the loss of Ubiad1 during
zebrafish development. We tested these variants for levels of
expression and CoQ10 synthesis in human ECs. Compared to
wild-type UBIAD1 protein, SCCD variants were expressed at
higher levels (Figure 5B). Furthermore, human ECs expressing
the UBIAD-SCCD mutant proteins produced higher CoQ10
levels compared to wild-type protein (Figures 6C and 6D).
Intriguingly, SCCD mutations did not affect cholesterol synthe-
sis in human ECs (Figure 5E). Although it remains unclear why
SCCD mutation would results in the SCCD phenotype, these
findings suggest that the SCCD variants are effective in CoQ10
production.
Ubiad1 and Coq2 Play Different Roles in CoQ10-
Mediated Cardiovascular Oxidative Protection
CoQ10 is a mobile lipophilic electron carrier critical for electron
transfer by the mitochondrial inner membrane respiratory chain
(Mitchell, 1961; Turunen et al., 2004; Duncan et al., 2009).
Primary CoQ10 deficiencies have been associated with muta-
tions in mitochondrial CoQ10 biosynthetic genes, such as
COQ2 (Salviati et al., 2005; Quinzii et al., 2006). In order to
investigate whether the Golgi-localized Ubiad1 and the mito-
chondrial-localized Coq2 can have different functions in vivo,
we knocked-down Coq2 expression during zebrafish develop-ment by morpholino (MO) injections. Similar to Drosophila sbo/
coq2 mutants (Liu et al., 2011), coq2 morphants are character-
ized by a general developmental delay, small body, and severe
hindbrain edema (Figures S5A–S5C). These phenotypes do not
occur in bar mutants or ubiad1 morphants, and, although a
strong increase in oxidative stress occurs in coq2 morphants
(Figure 6B), they did not show blood vessel regression (Fig-
ure 6A). Therefore, loss of Coq2 leads to oxidative stress, but
it does not significantly affect vascular integrity and survival.
We measured CoQ9 and CoQ10 levels, and as expected,
they dropped in coq2 and ubiad1 morphants, compared to
controls, and in double morphants (Figures 6C and S5D). Loss
of Ubiad1 and Coq2 in vivo unequivocally causes a decrease
in CoQ10 levels that possibly increases oxidative damage in
different subcellular compartments leading to different embry-
onic phenotypes.
To test whether Coq2 might compensate for loss of Ubiad1,
we performed rescue experiments by injecting mRNA encoding
for Coq2 in barmutants (Figure 6D). Although coq2mRNA injec-
tion could rescue coq2 morphants (data not shown) it did not
rescue bar mutants, suggesting that Coq2 does not protect
cardiovascular tissues from oxidative stress during zebrafish
development. MitoQ is a mitochondria-targeted antioxidant
(Murphy and Smith, 2007). Due to its selective accumulation
within mitochondria, MitoQ only protects against the mitochon-
drial oxidative damage that is caused in embryos and cells
by blocking mitochondrial CoQ10 synthesis through knocking
down Coq2 (Figure S5E). However, MitoQ (which will not interact
with the Golgi apparatus) did not rescue barmutants (Figure 6D),
indicating that the two different subcellular pools of CoQ10
contribute in quite distinct ways to the phenotype.
To demonstrate the existence of a functional difference
between the subcellular pools of CoQ10, we used human
primary ECs where we can silence UBIAD1 and COQ2 genes
at the same extent. Their silencing causes an increase in
oxidative stress and accumulation of oxidative damage (Fig-
ure 6E). To analyze the efficiency of UBIAD1 and COQ2 in total
CoQ10 biosynthesis, we performed labeled precursor experi-
ments where 4-hydroxybenzoic acid-13C6 was added to human
ECs previously transfected with siRNA for UBIAD1 (siUBIAD1)
or for COQ2 (siCOQ2) or both (Figure S5F). Silencing of
UBIAD1 or COQ2 individually or together significantly reduced
CoQ10-13C6 production. We also confirmed the efficiency of
UBIAD1 and COQ2 siRNAs in decreasing endogenous total
CoQ10 levels in ECs (Figure 6F). Interestingly, the silencing of
the UBIAD1 gene did not significantly interfere with the tran-
scriptional regulation of COQ2 and vice versa, indicating that
the effect on CoQ10 levels from the silencing of one gene is
not be altered by upregulation of the other (Figure 6G). We
then analyzed mitochondrial morphology and viability in ECs
that have been silenced for UBIAD1 or COQ2. The absence of
COQ2 significantly altered mitochondrial morphology (Figures
S5G and S5H) and mitochondrial membrane potential (Fig-
ure 6H), which can indeed be rescued by MitoQ (Figure S5I).
Mitochondrial damage could not be detected in UBIAD1-
silenced cells, indicating that the lack of the mitochondrial pool
of CoQ10 in COQ2-silenced cells exclusively impaired mito-
chondrial function.Cell 152, 504–518, January 31, 2013 ª2013 Elsevier Inc. 509
Figure 3. Block of Mevalonate Pathway Causes Cardiovascular Failure in Zebrafish Embryos by Reducing CoQ10 Synthesis
(A) Wild-type (WT) embryos at 72 hpf treated from 54 hpf with statin (mevastatin) or DMSO. Statin treatments induce a bar-like phenotype which is characterized
by hemorrhages (asterisk) and heart failure (arrowhead). Scale bar, 300 mm.
(B) Three dimensional projections of trunk vessels at 72 hpf of DMSO and statin-treated zebrafish embryos. Statin treatments induce specific endothelial vessels
regression and fragmentation in DA and Se (arrows). Scale bar, 100 mm.
(C) Quantification of bar-like phenotype after statin treatments. MEV, mevastatin 500 nM; SIM, simvastatin 500 nM; MEN, mevinolin 500 nM.
(D and E) Levels of CoQ10 (D) and cholesterol (E) detected by HPLC-UV analyses in statin-treated embryos.
(F andG) Bright-field (F) and fluorescent (G) images of Tg(kdrl:GFP)s843 ubiad1+/+ and ubiad1+/ embryos at 65 hpf treatedwithmevastatin (2.5 nM and 5 nM) from
32 to 50 hpf. Treatment with a low dose of statin caused hemorrhages (asterisks) and altered heart morphology (arrowheads) in ubiad1+/, but not in ubiad1+/+
embryos. Although treatment with a low dose of statin did not induce specific alterations of the main vasculature, ubiad1+/ embryos showed head vasculature,
Se, and DA regression; scale bar, 300 mm.
(legend continued on next page)
510 Cell 152, 504–518, January 31, 2013 ª2013 Elsevier Inc.
High levels of CoQ10 have been found in cellular membranes,
including the Golgi and plasma membranes (Kalen et al., 1987;
Turunen et al., 2004). The presence of CoQ10 in nonmitochon-
drial membranes has been associated with its role in protecting
membrane lipids from peroxidation as well as from an extracel-
lular-induced ceramide-dependent apoptotic pathway (Navas
et al., 2007). We evaluated oxidative degradation of lipids by
measuring lipid peroxidation in siUBIAD1-treatedcells (Figure 6I).
ECs without a cellular membrane pool of CoQ10 showed twice
the level of oxidized fatty acid lipids, indicating a functional role
for UBIAD1 in protection from oxidative species specifically
localized in cellular but not mitochondrial membrane. We con-
clude that UBIAD1-derived CoQ10 prevents lipid peroxidation
and propose a specific role for UBIAD1 in membrane protection
from oxidative damage.
UBIAD1 Prevents a Shear Stress/Klf2a/eNOS-Mediated
Oxidative Stress Pathway
A hemodynamic environment, such as shear stress, is known to
lead to ROS generation, which is responsible for vascular re-
modeling and angiogenesis (Matlung et al., 2009). Kruppel-like
factor 2 (Klf2) is an immediate mediator of hemodynamic forces
created by blood flow and regulates flow-dependent blood
vessel integrity both in zebrafish andmice (Lee et al., 2006; Nicoli
et al., 2010). By injecting cardiac troponin T2 (tnnt2) morpholino
to block blood circulation (Sehnert et al., 2002) and klf2a mor-
pholino (Nicoli et al., 2010) in barmutants, we detected a signifi-
cant delay of the bar phenotype as assessed by intersegmental
vessels (Se) disintegration (Figures S6A and S6B). klf2a mor-
pholino injection in barolo mutants lead to a partial recovery of
oxidative stress in ECs (Figure S6C). These data indicate that
a Klf2a-dependent shear stress pathway is required for oxidative
stress conditions in bar mutants and that loss of Ubiad1 in vivo
can be protected by impairment of this pathway.
In human endothelial cells KLF2 has been found to be directly
responsible for eNOS expression and signaling (Searles, 2006).
Recently, a blood-flow-dependent klf2a-NO signaling cascade
has been identified in developing zebrafish embryos (Wang
et al., 2011). Endothelial nos isoforms have been well character-
ized in zebrafish development (Fritsche et al., 2000; Pelster et al.,
2005; North et al., 2009;Wang et al., 2011). Inhibition of nos1 (the
zebrafish ortholog of mammalian endothelial Nos) expression
significantly rescued the barmutant phenotype as well as endo-
thelial regression (Figures 7A and 7B). Since abrogation of nos1
expression may interfere with HSC development and blood flow
we treated bar mutants at the onset of oxidative stress (32 hpf)
with the selective inhibitor of eNOS activity, N-nitro-L-arginine(H) Images of Tg(kdrl:GFP)s843 ubiad1+/+ and ubiad1+/ embryos trunk vasculature
but not in ubiad1+/+ embryos. Scale bar, 75 mm.
(I) Penetrance of bar-like phenotype at 65 hpf after treatment with mevastatin. ubia
than normal embryos (ubiad1+/+).
(J) CoQ10 supplemented embryos show less susceptibility to statin treatments in
the percentage of statin-treated embryos having bar-like phenotype after exoge
(K) CoQ10 supplementation before statin treatment prevents cardiac edema (ar
CoQ10-injected embryos after statin treatment. Scale bar, 300 mm.
(L) Histograms show oxidative stress in embryos after statin treatment with or w
All data are means ± SEM. ***p < 0.001.
See also Figure S3.methyl ester (L-NAME) (North et al., 2009). L-NAME treatment
promoted a full morphological and functional cardiovascular
recovery of a statistically significant number of bar mutants
(Figures 7C and 7D and S6E). This recovery was carefully evalu-
ated for ROS level and altered redox signaling (SNO-Cys stain-
ing) in ECs. Blocking of eNOS activity by L-NAME treatment
significantly reduced oxidative stress in endothelial cells of
bar embryos (Figure 7E) and restored normal redox signaling
(Figures 7F and S6E). Pronephric duct cells affected by oxidative
stress in bar mutants did not improve after L-NAME treatments
(Figure S6F). We also evaluated the effect of the NO donor
S-nitroso-N-acetyl-penicillamine (SNAP) on bar mutants. SNAP
treatments did aggravate the bar phenotype by increasing oxida-
tive species in these mutant embryos (Figures S6D–S6F). To test
whether the source of ROS in the absence of UBIAD1 was
caused by eNOS, we silenced eNOS in primary human ECs.
ROS levels could be fully normalized by reducing eNOS expres-
sion in siUBIAD1-treated cells (Figure 7G).
To verify that the NO-forming activity of eNOS was compro-
mised due to the lack of Ubiad1 and Golgi-CoQ10, wemeasured
NOS activity in bar mutants and human ECs silenced for
UBIAD1. The lack of Ubiad1 drastically reduced the formation
of NO in zebrafish embryos (Figure S6H) as well as in human
ECs (Figure 7H).
We measured tissue-specific NO levels in bar mutants by
imaging DAF-2DA staining in live embryos. NO accumulation
was reduced in the notochord (NC) and was completely absent
in the bulbus arteriosus (BuA) of bar mutants compared with
controls (Figure S6I). All together we show a specific role for
Ubiad1 on regulation of eNOS-mediated NO formation in endo-
thelial and cardiovascular cells in vivo.
These data indicate that the primary source of ROS causing
cardiovascular oxidative stress in bar mutant as well as in ECs
lacking UBIAD1 is dependent on eNOS activity. Therefore, we
propose an unexpected functional link in the Golgi compart-
ments between UBIAD1 and COQ10 in regulating eNOS activity
and eventually NO signaling during cardiovascular development
and homeostasis.
DISCUSSION
Ubiad1 Is a Prenyltranferase Enzyme Required for
CoQ10 Biosynthesis in Golgi Membranes
CoQ10 is an important cellular and mitochondrial redox com-
ponent and the only endogenously produced lipid-soluble anti-
oxidant (Bentinger et al., 2010). Although the genes encoding
for the CoQ10 biosynthetic enzymes have been identified inshow thinner and collapsed Se and DAmorphology in statin-treated ubiad1+/
d1+/ embryos are significantly more sensitive to develop a bar-like phenotype
terms of developing a bar-like phenotype as indicated by histograms showing
nous CoQ10 delivery.
rowhead) and brain hemorrhages (asterisk) in barolo. Images of vehicle- and
ithout CoQ10.
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Figure 4. UBIAD1 Is a Prenyltransferase Responsible for CoQ10 Synthesis in the Golgi Compartment
(A and B) Confocal images of human ECs showing Ubiad1 colocalization with Golgi markers. (A) DNA (blue), human Ubiad1(red), and TGN46 (green). (B) DNA
(blue), zebrafish Ubiad1-GFP (green), GM130 (red). Scale bar, 20 mm.
(C) High-magnification confocal images of Golgi compartment showing colocalization between Ubiad1-GFP (green) and the Golgi marker g-adaptin (red).
Scale bar, 10 mm.
(D) Fluorescence images of human ECs transfected with Ubiad1-GFP and treated or not with brefeldin A (+BFA). After BFA treatment, Ubiad1 localization
becomes diffuse throughout the cell. Scale bar, 10 mm.
(E) Golgi compartment (Golgi, ER, and endosome fractions) and mitochondrial fractions from human ECs were analyzed by western blot with the following
antibodies: g-Adaptin and Rab11, as marker for Golgi/ER/endosome fractions, HADHA (Hydroxyacyl-CoA Dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA
Hydratase [trifunctional protein], Alpha subunit) as marker for mitochondrial fractions.
(F) Levels of 13C6-isotope labeled CoQ10 (CoQ10-
13C6) detected byHPLC-MS. Compared to control (siCTRL) the level of CoQ10-
13C6 present in cells silenced for
UBIAD1 (siUBIAD1) is significantly reduced in Golgi compartment but not in mitochondria. Data are means ± SD. **p < 0.01.
See also Figure S4.
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Figure 5. SCCD UBIAD1 Variants Rescue
barolo Mutants and Positively Regulate
CoQ10 Synthesis
(A) wild-type UBIAD1 (WT) or SCCD UBIAD1 iso-
forms (N102S; D112G) rescue bar mutants at a
significant extent.
(B) Western blot analysis of protein extracts from
HUAEC transfected with plasmids encoding for
wild-type UBIAD1 (WT) or SCCD UBIAD1 isoforms
(N102S; D112G).
(C–E) HUAEC were transfected with plasmids
encoding for wild-type UBIAD1 (WT) or SCCD
UBIAD1 isoforms (N102S; D112G) and total lipid
extracts were quantitated for CoQ10-13C6 (C) and
CoQ10 by HPLC-MS (D) and for cholesterol by
HPLC-UV (E). Expression of all UBIAD1 proteins
rises levels of CoQ10 as well as de novo synthe-
tized CoQ10-13C but does not change cholesterol
levels in human ECs.
All data are means ± SEM. **p < 0.01, ***p < 0.001.bacteria and yeast, there is still only limited information about
these synthetic enzymes in vertebrates (Turunen et al., 2004).
The rate-limiting enzyme for the biosynthesis of CoQ10 is the
enzyme that catalyzes the condensation of the polyisoprenoid
chain with the benzoquinone ring. So far, the mitochondrial
COQ2 enzyme has been considered the only prenyltransferase
able to catalyze this reaction (Trevisson et al., 2011). Here, we
identified UBIAD1 as a vertebrate CoQ10 prenyltransferase.
UBIAD1 contains an UbiA prenyltransferase domain also present
in vertebrate COQ2. Although COQ2 encodes a mitochondrial
prenyltransferase, we found that UBIAD1 resides in the Golgi
compartment where it produces CoQ10. While the presence
of CoQ10 in nonmitochondrial membranes was previously ex-
plained by the existence of specific mechanisms for its redistri-
bution within the cell (Crane and Morre, 1977; Jonassen and
Clarke, 2000), our data now formally demonstrate that CoQ10
are synthetized in the Golgi compartment.
In favor of our hypothesis of a Golgi-synthetized CoQ10, it
has been recently reported that COQ6, COQ7, and COQ9, which
are critical enzymes for CoQ10 maturation, are also localized in
the Golgi compartment (Heeringa et al., 2011). Similarly, these
authors suggested that the Golgi-localized pool of CoQ10 may
function in specific cells as an essential antioxidant for plasma
membrane lipids that are normally derived from the Golgi
compartment.
In this work, we demonstrated that the two distinct ubiquinone
prenyltransferases act to resolve different molecular functions
inside the cells and in living organisms. We found that COQ2-
mediated CoQ10 production is mainly for mitochondrial respira-
tory chain function and energy production, whereas UBIAD1-
mediated CoQ10 production is important for membrane redox
signaling and protection from lipid peroxidation.
Ubiad1 and CoQ10: An Antioxidant System Controlling
Redox Cellular Membrane in Cardiovascular Tissues
Oxidative damage is caused by an imbalance between the
production of ROS and the antioxidant network. Although ROS
are predominantly implicated in causing cell damage and pre-
mature aging via oxidation of DNA, lipids, and proteins, theyalso play a major physiological role in several aspects of intra-
cellular signaling and regulation, especially in cardiovascular
tissues (Hare and Stamler, 2005; Kuster et al., 2010). Therefore,
heart, endothelial, and vascular smooth-muscle cells need an
efficient antioxidant network to balance ROS levels. We have
shown a set of genetic and cellular data that reveal an unex-
pected role for UBIAD1 as an essential antioxidant gene with
important functions in the protection of heart and endothelial
cells from oxidative stress at the level of cellular membranes
by producing CoQ10 in theGolgi for distribution to nonmitochon-
drial membranes throughout the cell. In addition to its crucial role
in oxidative phosphorylation, CoQ10 plays another vital role in
cellular function as an antioxidant molecule. The antioxidant
nature of CoQ10 is derived from its function as an electron
carrier: in this role, CoQ10 continually shuttles between oxidized
and reduced forms. As it accepts electrons, it becomes reduced.
As it gives up electrons, it becomes oxidized. In its reduced ubiq-
uinol form, the CoQ10molecule will quite easily give up one elec-
tron, and thus act as an antioxidant. In such a way, CoQ10
inhibits lipid peroxidation by acting as a chain breaking antioxi-
dant. Moreover, CoQH2 reduces the initial lipid peroxyl radical,
with concomitant formation of ubisemiquinone and an alkyl per-
oxide. This quenching of the initiating peroxyl radicals thereby
prevents the propagation of lipid peroxidation and protects not
only lipids, but also proteins from oxidation. In addition, the
reduced form of CoQ10 might also contribute to the stabilization
of the plasma membrane, regenerating antioxidants such as
a-tocopherol. A crucial role in all these processes is played by
NAD(P)H-dependent reductase(s) acting at the plasma mem-
brane to regenerate the reduced ubiquinol form of CoQ10,
contributing to the maintainance of its antioxidant properties
(Navas et al., 2007). This finding also opens an interesting link
among cellular redox-state and metabolic pathways such as
the mevalonate pathway.
An Essential Function for Ubiad1/CoQ10 in Regulation
of NO Signaling
We have demonstrated that UBIAD1 protects cardiovascular tis-
sue from ROS-mediated oxidative stress by producing CoQ10Cell 152, 504–518, January 31, 2013 ª2013 Elsevier Inc. 513
Figure 6. Ubiad1 and Coq2 Play Different
Functions during Development
(A) Se integrity is affected in Tg(kdrl:GFP)s843
embryos injected with ubiad1 morpholino (ubiad1
MO) but not in coq2 morphants (coq2 MO). Scale
bar, 100 mm.
(B) Oxidative stress levels in entire ubiad1 mor-
phants (ubiad1 MO), coq2 morphants (coq2 MO),
and relative control (ctrl MO).
(C) CoQ10 levels detected by HPLC-MS are
significantly lower in ubiad1 morphants (ubiad1
MO), coq2 morphants (coq2 MO), ubiad1 and
coq2 double morphants (ubiad1+ coq2 MO) than
control morphants (ctrl MO).
(D) Embryos from bar heterozygote intercrosses
were injected with coq2mRNA and mitochondria-
targeted CoQ10 analog called MitoQ (10 mM) or
cherrymRNAandDecyl-TPP (10 mM) as respective
controls. Phenotypes were scored at 72 hpf. bar
phenotype is not caused by lack of mitochondria
CoQ10.
(E) Silencing of both CoQ10 biosynthetic enzymes
(siUBIAD1 and siCOQ2) cause increase of total
cellular ROS in ECs.
(F) Levels of CoQ10 detected by HPLC-MS in
total lipid extracts from HUAEC silenced for
UBIAD1 (siUBIAD1), COQ2 (siCOQ2), or both
(siUBIAD1+siCOQ2). UBIAD1 and COQ2 were
silenced with 50 pmoles (black bars) or with 100
pmoles (gray bars). Levels of CoQ10 are signifi-
cantly reduced in cells silenced for UBIAD1 or
COQ2 expression.
(G) Quantitative PCR analyses of UBIAD1 and
COQ2 mRNA levels in HUAEC cells.
(H) Quantification of loss of mitochondrial mem-
brane potential (Dcm) in HUAEC silenced for
UBIAD1 (siUBIAD1) or COQ2 (siCOQ2).
(I) Quantification of lipid peroxidation by MDA
adducts levels in HUAEC silenced for UBIAD1
(siUBIAD1) or COQ2(siCOQ2).
All data are means ± SD. **p < 0.01, ***p < 0.001.
See also Figure S5.located in Golgi and plasma membranes. Major enzymatic
pathways responsible for the generation of ROS in cardiovas-
cular tissues are mainly NADPH oxidases and eNOS (Browning
et al., 2012). By using drug inhibition and gene inactivation
approaches, we identify eNOS dysfunction as the primary
cause of ROS increase in bar mutant and UBIAD1-silenced
human ECs. The NO synthetized by eNOS is an essential fac-
tor for cardiovascular development and homeostasis in verte-
brates (Alp and Channon, 2004; Pelster et al., 2005; North
et al., 2009; Wang et al., 2011). It has been suggested that
CoQ10 might have a positive role in modulating NO-related
pathways by recoupling eNOS in endothelial cells (Stuehr
et al., 2001; Chew and Watts, 2004; Tsai et al., 2012). eNOS
is a ‘‘L-arginine, NADPH:oxygen oxidoreductases, NO-forming
enzyme’’ (EC 1.14.13.39) that couples reduction of molecular
oxygen to L-arginine oxidation and generation of L-citrulline
and NO. eNOS controls the flow of electrons donated by NADPH
to flavins FAD and FMN in the reductase domain of one
monomer through BH4 to the ferrous-dioxygen complex (Fe)
in the oxygenase domain. When NADPH and BH4 cofactors514 Cell 152, 504–518, January 31, 2013 ª2013 Elsevier Inc.are limiting, electron transfer becomes uncoupled from L-argi-
nine oxidation, the ferrous–dioxygen complex dissociates, and
superoxide (,O2
) is generated from the oxygenase domain
(Schmidt and Alp, 2007).
Our data indicate that barolo mutants lacking the Golgi pool
of CoQ10 die due to the accumulation of oxidative damage in
cardiovascular tissues caused by ROS produced by eNOS.
We suggest a mechanism whereby UBIAD1 is required in the
Golgi compartment to produce CoQ10 as an important
cofactor for eNOS-mediated NO production (Figure 7I). This
model could fit with the oxido-reductive properties of CoQ10
and eNOS: the electron flux inside eNOS that is mandatory to
produce NO from L-arginine might require CoQ10, together
with NADPH and BH4. Such function would not be very
different from what CoQ10 does in the mitochondrial electron
transport chain (ETC) coupling electron transfer between an
electron donor (such as NADH) and an electron acceptor
(such as O2) with the transfer of H
+ ions across the mitochon-
drial inner membrane. In the Golgi membranes, the flow of elec-
trons within eNOS transfers electrons from NADPH to the
Figure 7. NOS Activity in Cardiovascular Tissues Is Regulated by UBIAD1 and CoQ10
(A) Knockdown of endothelial nitric oxide synthase 1 by morpholino (nos1 MO) reduces the penetrance of bar phenotype at 72 hpf.
(B) Knockdown of nos1 rescue endothelial integrity defects of barmutants. Images of Se of bar at 72 hpf injected with nos1morpholino (bar + nos1MO) or control
morpholino (bar + ctrl MO) Scale bar, 50 mm.
(legend continued on next page)
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flavins FAD and FMN, which have the capacity to reduce
molecular oxygen. If the ETC is disturbed, such as in the
absence of UBIAD1/CoQ10, the ferrous-dioxygen complex
dissociates, and O2 is generated from the FMN oxygenase
domain (Liu et al., 2002; Rigoulet et al., 2011). In cardiovascular
tissues, the CoQ10 produced by UBIAD1 in the Golgi compart-
ment may be an important cofactor to maintain eNOS in
a coupled conformation (e.g., required to produce physiological
NO) and, eventually, quench leaking-uncoupled electrons. We
speculate that when UBIAD1/CoQ10 in the Golgi compartment
is absent or decreased (bar mutants and siUBIAD1-treated
cells) eNOS switches to an ‘‘uncoupled’’ conformation,
producing oxidative species instead of NO and causing cardio-
vascular oxidative damage (Figure 7I). Further experiments
need to be done to assess this hypothesis as well as the possi-
bility that other NOS (e.g., nNOS) could be affected by the lack
of Ubiad1 in vivo.
In summary, our study places UBIAD1 in a pathway with
important therapeutic implications for cardiovascular failure,
such as the opportunity to decrease oxidative damage and
counteract some of the side effects of statins. In addition,
pharmacological or genetic stimulation of UBIAD1, as a CoQ10
biosynthetic enzyme, represents a promising therapeutic
approach for antioxidant-related diseases such as aging and
cancer.
EXPERIMENTAL PROCEDURES
Zebrafish Strains, Mapping, Genotyping
Embryos and adult fishes were raised and maintained under standard labora-
tory conditions. bars847 and bart31131 mutants were generated by ENU muta-
genesis as previously described (Jin et al., 2007).
Oxidative Stress Analyses in Zebrafish Embryos and Cells
Oxidative damage was detected by immunofluorescence on agarose sections
of zebrafish embryos with the following markers: anti-8-hydroxy-20-deoxygua-
nosine (1:500, Abcam) and anti-S-nitroso-cysteine (1:250, Sigma).
ROS levels were quantitated in isolated human (HUAEC) and zebrafish
(Tg(Kdrl:GFP)s843) endothelial cells with CellROX Deep Red Reagent (Invitro-
gen; 2.5 mM) and analyzed by FACS.
Generation of Human SCCD Mutation in UBIAD1
Constructs containing the SCCDmutation N102S and D112Gwere introduced
in pCS2+ plasmids and used for expression in zebrafish embryos as well as
human ECs.(C) Bright-field images (left) and fluorescent micrographs showing the trunk vascu
inhibitor L-NAME (500 mM). Heart failure (arrowhead) and endothelial regression
(D) Penetrance of the bar phenotype at 65 hpf is significantly decreased by inhib
(E) Oxidative stress level in ECs derived from Tg(kdrl:GFP)s843 bar mutant embry
(F) eNOS inhibition by L-NAME treatment significantly reduces ECs positive for S
(G) Silencing of eNOS (sieNOS) rescues oxidative stress induced by the lack of U
(H) Silencing of UBIAD1 gene (siUBIAD1) causes a significant decrease of eNOS
(I) Schematic representation of Ubiad1molecular function in CoQ10 production an
in the Golgi compartment and produces CoenzymeQ10 (CoQ10), an antioxidan
membranes (cytosol and plasma membrane). In the Golgi compartment CoQ10 a
activity by maintaining its ‘‘coupled’’ conformation and allowing normal NO produ
the cardiovascular tissues of barmutants, might ‘‘uncouple’’ eNOS causing loss o
cellular oxidative damage (e.g., lipid peroxidation). Thereby, the ‘‘barolo’’ phenot
Data are means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S6.
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NOS activity was assayed using the NOS Activity Assay Kit (Cayman Chemi-
cals). NO levels were detected using the DAF-2 DA (Calbiochem).
Cell Culture Experiments
Human primary EC were purchased from Lonza and cultured according to the
manufacturer’s protocols (Lonza). Cells were electroporated with siRNA
(Dharmacon).
HPLC Analyses
Samples for HPLC-MS analysis were zebrafish embryos (n = 25) or human
HUAEC (2 3 106 cells). CoQ10 and CoQ9 levels were detected by HPLC-
MS or HPLC-UV (as indicated). Total cholesterol from zebrafish embryos
was analyzed by HPLC-UV. 4-Hydroxy-benzoic acid-13C6 was stocked in
Dulbecco’s modified Eagle’s medium (DMSO) and dissolved in cell culture
medium (1 mM) or microinjected in zebrafish embryo at one cell stage
(2 mM). ECs or embryos were extracted after 48 or 72 hr, respectively, after
labeled precursor administration. Extracts were quantified by HPLC-MS as
described.
Exogenous CoQ10 and Vitamin K Administration
All chemicals and solvents for liposomal CoQ10 and Vitamin K formulation
were purchased from Sigma Aldrich and Avanti Polar Lipids. Liposomal
SINAMIT was a gift from Dr. Franz Enzmann (MSE Pharmazeutika GmbHT),
liposomal LiQsorb was from Tishcon Corp. MitoQ was synthetized as previ-
ously reported (Murphy and Smith, 2007). All CoQ10 and vitamin K formula-
tions were tested for toxicity and microinjected at specific concentrations
into zebrafish embryos at one cell stage.
For detailed procedure of refer to Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, one table, and four movies and can be found with this article online
at http://dx.doi.org/10.1016/j.cell.2013.01.013.
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